Document is current
Any future updates will be listed below
-
Authors
Lam, Chih Chiang Benjamin https://orcid.org/0000-0002-1482-5148
Mina, Theresia https://orcid.org/0000-0002-5360-9915
Xie, Wubin
Low, Yanwen Dorrain https://orcid.org/0000-0002-7742-3189
Yew, Yik Weng https://orcid.org/0000-0001-8915-306X
Wang, Xiaoyan
Riboli, Elio
Elliott, Paul https://orcid.org/0000-0002-7511-5684
Lee, Jimmy https://orcid.org/0000-0002-7724-7445
Ngeow, Joanne https://orcid.org/0000-0003-1558-3627
Lee, Eng Sing https://orcid.org/0000-0003-4963-535X
Loh, Marie https://orcid.org/0000-0003-3626-8466
Chambers, John C.
- License Information
-
More Information
Article History
Received: 23 April 2024
Revised: 23 October 2024
Accepted: 28 October 2024
First Online: 19 November 2024
Conflict of interest
: BCCL had served as an advisory board member for Novo Nordisk, and a speaker for Novo Nordisk, Abbott and DKSH. JL had served as a consultant or advisory board member from Otsuka, Janssen, Lundbeck, Sumitomo Pharmaceuticals, Boehringer Ingelheim and ThoughtFull World Pte. Ltd.
: The HELIOS study was approved by the National Technological University (NTU) Institutional Review Board (reference: IRB-2016-11-030), with written informed consent obtained from each participant before the commencement of the study. All methods were performed in accordance with the relevant guidelines and regulations.
